PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+11.69%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$3.38B
AUM Growth
+$3.38B
(-2.6%)
Cap. Flow
+$174M
Cap. Flow
% of AUM
5.16%
Top 10 Holdings %
Top 10 Hldgs %
46.51%
Holding
114
New
18
Increased
20
Reduced
21
Closed
14
Top Buys
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$197M |
| 2 |
Orchestra BioMed
OBIO
|
$44.6M |
| 3 |
Sanofi
SNY
|
$41.8M |
| 4 |
Arcellx
ACLX
|
$38.3M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$36.6M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Natera
NTRA
$23B
| $39.3M | 1.16% |
707,214
+577,214
| +444% | +$32M |
|
27
Acrivon Therapeutics
ACRV
$42.2M
| $38.2M | 1.13% |
3,007,858
| – | – |
|
|
28
Apellis Pharmaceuticals
APLS
$3.51B
| $36.6M | 1.08% |
+555,344
| New | +$36.6M |
|
29
MeiraGTx Holdings
MGTX
$590M
| $36M | 1.06% |
6,963,277
| – | – |
|
30
Sarepta Therapeutics
SRPT
$1.98B
| $36M | 1.06% |
260,858
-388,392
| -60% | -$53.5M |
|
|
BLU
31
DELISTED
BELLUS Health Inc.
BLU
| $35.7M | 1.05% |
4,952,538
-3,938,489
| -44% | -$28.4M |
|
|
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
| $34M | 1% |
3,903,255
+3,194,262
| +451% | +$27.9M |
|
33
Verrica Pharmaceuticals
VRCA
$49.4M
| $32.8M | 0.97% |
5,038,983
| – | – |
|
34
Relay Therapeutics
RLAY
$709M
| $32M | 0.94% |
1,943,097
| – | – |
|
35
Establishment Labs
ESTA
$1.11B
| $31.7M | 0.94% |
467,857
-30,000
| -6% | -$2.03M |
|
36
BridgeBio Pharma
BBIO
$9.91B
| $31.6M | 0.93% |
1,907,033
+210,000
| +12% | +$3.48M |
|
37
Zymeworks
ZYME
$1.07B
| $30.5M | 0.9% |
3,378,498
-1,132,777
| -25% | -$10.2M |
|
38
Astria Therapeutics
ATXS
$394M
| $29.1M | 0.86% |
2,189,462
| – | – |
|
39
Nautilus Biotechnolgy
NAUT
$80.7M
| $25.2M | 0.75% |
9,111,151
| – | – |
|
40
Cogent Biosciences
COGT
$1.83B
| $24.6M | 0.73% |
2,282,324
-925,117
| -29% | -$9.98M |
|
41
Immatics
IMTX
$662M
| $24.1M | 0.71% |
3,491,500
| – | – |
|
42
Protagonist Therapeutics
PTGX
$3.62B
| $22.2M | 0.66% |
+965,152
| New | +$22.2M |
|
43
Outset Medical
OM
$245M
| $20M | 0.59% |
1,089,427
| – | – |
|
44
Immunovant
IMVT
$2.91B
| $20M | 0.59% |
1,291,858
+1,141,858
| +761% | +$17.7M |
|
45
Akero Therapeutics
AKRO
$3.65B
| $20M | 0.59% |
523,525
+173,000
| +49% | +$6.62M |
|
46
Roivant Sciences
ROIV
$8.6B
| $19.9M | 0.59% |
2,692,136
+710,566
| +36% | +$5.24M |
|
47
Lyra Therapeutics
LYRA
$11.8M
| $18.4M | 0.54% |
9,146,730
| – | – |
|
48
Solid Biosciences
SLDB
$448M
| $16.6M | 0.49% |
3,495,933
| – | – |
|
49
Tarsus Pharmaceuticals
TARS
$2.44B
| $16.3M | 0.48% |
1,296,416
| – | – |
|
50
Terns Pharmaceuticals
TERN
$651M
| $16M | 0.47% |
+1,350,000
| New | +$16M |
|